Indications
Recarbrio is indicated for:- Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults (see sections 4.4 and 5.1).- Treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.- Treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4, and 5.1).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Composition
- Active substance
- imipenem monohydrate, cilastatin sodium, relebactam monohydrate
- International name (INN)
- imipenem;cilastatin;relebactam
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Recarbrio
- Active substance
- imipenem monohydrate, cilastatin sodium, relebactam monohydrate
- ATC code